Evaluation of the Efficacy and Tolerability of Oral Ciprofloxacin used in the Comprehensive Treatment of External Bacterial Otitis: An Observational Prospective Study
04 August 2016
28 November 2016
17 February 2017 (eFirst)
Introduction Otitis Externa is common ear infection with a prevalence of 1%.
Objective The objective of this study is to evaluate the clinical and microbiological efficacy and safety profile with oral ciprofloxacin in the external bacterial otitis (EBO) management.
Methods This is a prospective observational study conducted with EBO outpatients referred to the otorhinolaryngology center in Moscow between March and August 2013. Our study included patients from two cohorts, acute external bacterial otitis (AEBO) - Group 1 - and exacerbation of chronic otitis externa (CEBO) - Group 2. We administered Ciprofloxacin 500 mg twice daily with standard topical EBO treatment for up to 10 days. Patients underwent evaluation on study visit days 1, 3, 5, and 10 for the severity. Bacteriological examination of ear canal cultures took place on Day 1 and Day 10.
Results We collected data from 60 EBO outpatients (AEBO: N = 30 and CEBO: N = 30). Swimming was the major risk factor associated with the disease in addition to the most common pathogenic organisms - Staphylococcus aureus and Pseudomonas aeruginosa. was We attained complete resolution of the inflammatory process in 28 (93%) and 27 (90%) patients in the AEBO and CEBO group, respectively. We confirmed this by microbiological test with almost complete eradication of the causative organisms. Overall, we observed good positive dynamics of ear canal with no major side effects.
Conclusion We found that Ciprofloxacin 500 mg, when administered orally twice daily for 7 to 10 days in otitis externa patients is clinically and microbiologically effective and comparatively safer than other antimicrobials.
This trial is registered with http://clinicaltrials.gov, number NCT02140073.
- 1 van Balen FAM, Smit WM, Zuithoff NPA, Verheij TJM. Clinical efficacy of three common treatments in acute otitis externa in primary care: randomised controlled trial. BMJ 2003; 327 (7425): 1201-1205
- 2 Hajioff D, Mackeith S. Otitis externa. BMJ Clin Evid 2010; 2010: 510
- 3 Osguthorpe JD, Nielsen DR. Otitis externa: Review and clinical update. Am Fam Physician 2006; 74 (09) 1510-1516
- 4 Louie TJ. ; Committee on Antimicrobial Agents. Canadian Infectious Disease Society. Ciprofloxacin: an oral quinolone for the treatment of infections with gram-negative pathogens. CMAJ 1994; 150 (05) 669-676
- 5 Jayakar R, Sanders J, Jones E. A study of acute otitis externa at Wellington Hospital, 2007-2011. Australas Med J 2014; 7 (10) 392-399
- 6 Sander R. Otitis externa: a practical guide to treatment and prevention. Am Fam Physician 2001; 63 (05) 927-936 , 941–942
- 7 Pabla L, Jindal M, Latif K. The management of otitis externa in UK general practice. Eur Arch Otorhinolaryngol 2012; 269 (03) 753-756
- 8 Rowlands S, Devalia H, Smith C, Hubbard R, Dean A. Otitis externa in UK general practice: a survey using the UK General Practice Research Database. Br J Gen Pract 2001; 51 (468) 533-538
- 9 Rosenfeld RM, Schwartz SR, Cannon CR. , et al. Clinical practice guideline: acute otitis externa. Otolaryngol Head Neck Surg 2014; 150 (1, Suppl) S1-S24
- 10 Roland PS, Younis R, Wall GM. A comparison of ciprofloxacin/dexamethasone with neomycin/polymyxin/hydrocortisone for otitis externa pain. Adv Ther 2007; 24 (03) 671-675
- 11 Agius AM, Pickles JM, Burch KL. A prospective study of otitis externa. Clin Otolaryngol Allied Sci 1992; 17 (02) 150-154
- 12 Mösges R, Nematian-Samani M, Hellmich M, Shah-Hosseini K. A meta-analysis of the efficacy of quinolone containing otics in comparison to antibiotic-steroid combination drugs in the local treatment of otitis externa. Curr Med Res Opin 2011; 27 (10) 2053-2060